Warm Autoimmune Hemolytic Anemia Clinical Trials

24 clinical trials for Warm Autoimmune Hemolytic Anemia across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease — RECRUITING · PHASE1
• Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab — RECRUITING · PHASE2
• Sirolimus in the Treatment of Refractory/Relapsed wAIHA — RECRUITING · NA
• Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia — ACTIVE_NOT_RECRUITING · PHASE2
• A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA — NOT_YET_RECRUITING · PHASE1
• An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias — ACTIVE_NOT_RECRUITING · PHASE1
• A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia — ACTIVE_NOT_RECRUITING · PHASE3
• Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double blind, Placebo controlled Study with a Long-term Open-label Extension — TERMINATED · PHASE3
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA) — COMPLETED · PHASE2
• Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA) — ACTIVE_NOT_RECRUITING · PHASE2
• Post-trial Access for Nipocalimab in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA) — OTHER
• Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia — TERMINATED · PHASE3
• A multicenter, open-label, Phase IIb study to evaluate the efficacy, safety and pharmacokinetics of rilzabrutinib in patients with warm autoimmune hemolytic anemia (LUMINA 2) — TERMINATED · PHASE2
• A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre) — ACTIVE_NOT_RECRUITING · PHASE3
• Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD) — COMPLETED · PHASE2
• Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA) — TERMINATED · PHASE2
• Zanubrutinib in the Treatment of Relapsed/Refractory wAIHA — OTHER · PHASE2
• To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA). — TERMINATED · PHASE2
• Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disorders — COMPLETED · PHASE1
• Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia — WITHDRAWN · PHASE2
• ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia — WITHDRAWN · PHASE2
• A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA) — TERMINATED · PHASE1
• Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune Cytopenia — WITHDRAWN · PHASE2
• Rituximab in Auto-Immune Hemolytic Anemia — COMPLETED · PHASE3

Refine this search